[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Entrada Therapeutics Inc (TRDA)

Entrada Therapeutics Inc (TRDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 254,666
  • Shares Outstanding, K 38,821
  • Annual Sales, $ 25,420 K
  • Annual Income, $ -143,750 K
  • EBIT $ -178 M
  • EBITDA $ -178 M
  • 60-Month Beta -0.09
  • Price/Sales 9.64
  • Price/Cash Flow N/A
  • Price/Book 0.90

Options Overview Details

View History
  • Implied Volatility 194.19% (+19.19%)
  • Historical Volatility 251.69%
  • IV Percentile 21%
  • IV Rank 14.18%
  • IV High 1,251.56% on 09/10/25
  • IV Low 19.44% on 09/09/25
  • Expected Move (DTE 25) 1.79 (27.21%)
  • Put/Call Vol Ratio 0.50
  • Today's Volume 3
  • Volume Avg (30-Day) 51
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 742
  • Open Int (30-Day) 861
  • Expected Range 4.78 to 8.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.16
  • Number of Estimates 4
  • High Estimate $-0.99
  • Low Estimate $-1.34
  • Prior Year $-1.04
  • Growth Rate Est. (year over year) -11.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.63 +16.52%
on 05/19/26
16.45 -60.12%
on 05/06/26
-6.49 (-49.73%)
since 04/22/26
3-Month
5.63 +16.52%
on 05/19/26
16.45 -60.12%
on 05/06/26
-4.73 (-41.90%)
since 02/20/26
52-Week
4.93 +33.06%
on 08/11/25
16.45 -60.12%
on 05/06/26
-1.06 (-13.91%)
since 05/22/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

NEW YORK , May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such investors are...

TRDA : 6.56 (+3.96%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

NEW YORK , May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA).  Such investors are...

TRDA : 6.56 (+3.96%)
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile

Entrada Therapeutics (NASDAQ:TRDA) said initial data from the first cohort of its phase I/II ELEVATE-44-201 trial showed favorable safety and tolerability and early functional improvement in ambulatory...

TRDA : 6.56 (+3.96%)
Entrada Therapeutics Reports First Quarter 2026 Financial Results

-- Announced positive ELEVATE-44-201 Cohort 1 topline results in Duchenne muscular dystrophy showing favorable safety, tolerability and early functional benefit -- -- Company on track to report ELEVATE-45-201...

TRDA : 6.56 (+3.96%)
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study

-- Achieved the primary objective with favorable safety and tolerability, no discontinuations and no serious adverse events -- -- Markers of kidney function via eGFR, Cystatin C and magnesium were...

TRDA : 6.56 (+3.96%)
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026

BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) will announce topline results from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion...

TRDA : 6.56 (+3.96%)
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 12,990 restricted stock units (“RSUs”) to two newly-hired...

TRDA : 6.56 (+3.96%)
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

– Company on track to report ELEVATE-44-201 data from Cohort 1 in Q2 2026 and Cohort 2 by year-end 2026 – – Company on track to report ELEVATE-45-201 data from Cohort 1 in mid-2026 – ...

TRDA : 6.56 (+3.96%)
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

-- Patients in Cohort 1 have progressed to the open label, Phase 2 portion of ELEVATE-44-201  -- -- Company on track to report ELEVATE-44-201 Cohort 1 data in Q2 2026, with Cohort 2  data by end...

TRDA : 6.56 (+3.96%)
Entrada Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the Company will participate in two upcoming investor conferences. Guggenheim Emerging Outlook:...

TRDA : 6.56 (+3.96%)

Business Summary

Entrada Therapeutics Inc. is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles(TM) to engage intracellular targets. Entrada Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 7.05
2nd Resistance Point 6.91
1st Resistance Point 6.73
Last Price 6.56
1st Support Level 6.41
2nd Support Level 6.27
3rd Support Level 6.09

See More

52-Week High 16.45
Fibonacci 61.8% 12.05
Fibonacci 50% 10.69
Fibonacci 38.2% 9.33
Last Price 6.56
52-Week Low 4.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.